IL2 and neoplasm: To overcome the toxicity related to the systemic administration of IL-2 at high-dose, diverse IL-2 immunocytokines composed of IL-2 fused to antibodies directed against tumor-associated antigens (TAAs) have been tested in preclinical models with promising results (10, 19–48).